Carnitine palmitoyltransferase 1B mediates gemcitabine resistance in pancreatic cancer

The incidence of pancreatic cancer is rising, with pancreatic ductal adenocarcinoma (PDAC) accounting for approximately 90% of all pancreatic cancers.1 A diagnosis of PDAC is especially grim, with 5-year survival rates currently at 13% just this year. The commonality among National Comprehensive Cancer Network clinical practice guidelines is the recommendation to undergo chemotherapy, although timing depends on alternative treatment modalities, such as surgery and radiation, which is dependent on staging, resectability, and surgical candidacy.
Source: Surgery - Category: Surgery Authors: Source Type: research